Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating belimumab as an additional treatment for adults with interstitial lung disease ILD linked to connective tissue diseases CTDs such as rheumatoid arthritis, systemic lupus erythematosus, and others. ILD leads to lung inflammation and stiffness, causing symptoms like shortness of breath and cough, which significantly reduce quality of life and are the main cause of death in these patients. This study aims to see if belimumab combined with standard therapy can stabilize or improve lung function and ILD symptoms while maintaining an acceptable safety profile. Participants are randomly assigned to receive either belimumab or a placebo, both alongside standard therapy. Belimumab is given by subcutaneous injection. The study lasts for 52 weeks with treatment and monitoring occurring throughout this period. The primary measurement is the change in lung function, specifically forced vital capacity FVC, from baseline to week 52. Various secondary measures assess lung symptoms, fatigue, quality of life, lung imaging, and safety outcomes. During the study, participants will have assessments at baseline and week 52 including lung function tests, symptom questionnaires, and imaging scans. Researchers will track changes in lung capacity, disease progression, symptom severity, fatigue, and medication use. Safety monitoring continues up to week 60 to record adverse events and hospitalizations related to respiratory issues. Participants will be involved in regular visits for evaluation and medication administration over the course of the year-long study.
Actively Recruiting
This research aims to study children and adolescents aged 2 to 17 years who have fibrosing interstitial lung disease ILD. The trial evaluates how the drug nerandomilast is tolerated, processed by the body, and whether it helps young patients with ILD. Nerandomilast has been approved in some countries for adults with a similar lung condition called idiopathic pulmonary fibrosis. The study is designed to better understand the effects and safety of nerandomilast in this younger population. Participants aged 6 to 17 years are randomly assigned to one of two groups for the first part of the study one group receives nerandomilast, and the other receives a placebo that looks like the medicine but contains no active drug. They take tablets twice daily for 6 months. After this, all participants in this age group receive nerandomilast for at least 2 years in the second part of the study. Younger participants aged 2 to 5 years start nerandomilast treatment immediately and take the tablets twice daily for at least two and a half years. Over the course of the study, which lasts between two and a half to five years depending on when participants join, individuals may have about 18 to 30 visits to the study site. During these visits, doctors collect blood samples to monitor health and how the body handles the medicine. Lung function, growth, and quality of life are also regularly assessed. For participants aged 6 to 17 years, results from the nerandomilast group are compared to those receiving placebo to evaluate treatment effects.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.